General description

A panel containing 15 potent and selective inhibitors useful for the study of VEGF signaling pathways. This panel contains the following inhibitors and 15 ml anhydrous DMSO for reconstitution:

A panel containing 15 potent, selective, reversible, and cell-permeable inhibitors useful for the study of multiple signaling pathways activated by VEGF: 1 mg of Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 (Cat. No. 124018); 1 mg of Calcineurin Autoinhibitory Peptide, Cell-permeable (Cat. No. 207001); 5 mg of ET-18-OCH3 (Cat. No. 341207); 500 µg of Go 6983 (Cat. No. 365251); 100 mg of N^G-Nitro-L-arginine Methyl Ester, Hydrochloride (Cat. No. 483125); 5 mg of p21-Activated Kinase Inhibitor III, IPA-3 (Cat. No. 506106); 500 µg of cPLA2α Inhibitor (Cat. No. 525143); 1 mg of PI-103 (Cat. No. 528100); 1 mg of PP2 (Cat. No. 529573); 1 mg of SB 203580 (Cat. No. 559389); 1 mg of U0126 (Cat. No. 662005); 5 mg of VEGFR Tyrosine Kinase Inhibitor V (Cat. No. 676501), 5 mg of VEGFR2 Kinase Inhibitor VI, Ki8751 (Cat. No. 676484); 1 mg of VEGFR2 Kinase Inhibitor III, SU5416 (Cat. No. 676487); 1 mg of ZM 336372 (Cat. No. 692000). Also provided with 15 ml of anhydrous DMSO (Cat. No. KP31817). Supplied with a data sheet.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C) each inhibitor. Each inhibitor solution is stable for up to 3 months at -20°C, except 662005, which is unstable in solution, and should be reconstituted just prior to use.

Please refer to information provided on the CD for reconstitution information of individual inhibitors.

Warning

Toxicity: Standard Handling (A)